Replimune Group, Inc.
Replimune Group, Inc. (REPL): 18 pipeline candidates · 5 upcoming catalysts · ~12 mo cash runway · 24 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
12.1 months
D/E 0.58 · 16% dilution
Lead: Phase 3
18 candidates
5 upcoming, next in ~54d
0 buys · 8 sells (180d)
A transparent, data-derived signal for Replimune Group, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$825.7M
Cash
$124.7M
Quarterly Burn
$66.0M
Runway
12.1 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| 4D-125 IVT Injection | Phase 2 |
| AAV5-hRKp.RPGR | Phase 3 |
| cemiplimab | Phase 2 |
| Control | Phase 3 |
| Filgrastim | Phase 2 |
| Genetic | Phase 3 |
| Pegfilgrastim | Phase 2 |
| rAAV2tYF-GRK1-hRPGRco | Phase 2 |
| rp1 | Phase 2 |
| RP1 (vusolimogene oderparepvec) | Phase 3 |
Showing 10 of 18 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
187
Total value held
$633.7M
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 11,045,336 | $84.5M |
| rtw investments, lp | 7,356,916 | $56.3M |
| blackrock, inc. | 6,239,239 | $47.7M |
| vanguard capital management llc | 5,518,240 | $42.2M |
| suvretta capital management, llc | 4,221,836 | $32.3M |
| state street corp | 3,782,237 | $28.9M |
| fcpm iii services b.v. | 2,808,368 | $21.5M |
| d. e. shaw & co., inc. | 2,336,528 | $17.9M |
| susquehanna international group, llp | 2,320,879 | $17.8M |
| goldman sachs group inc | 2,277,276 | $17.4M |
Showing top 10 of 187 institutional holders of Replimune Group, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Replimune Group, Inc.'s pipeline?
Replimune Group, Inc. (REPL) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Replimune Group, Inc.'s lead drug candidate?
Replimune Group, Inc.'s most advanced tracked candidate is 4D-125 IVT Injection (Phase 2) for High-Risk Oral Precancerous Disease.
What is Replimune Group, Inc.'s next catalyst?
Replimune Group, Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2 Study of RP2 With Tivozanib in Patients With Metastatic Renal Carcinoma After Progression " — expected August 11, 2026.
What is Replimune Group, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Replimune Group, Inc. has approximately 12.1 months of cash runway.
What is Replimune Group, Inc.'s market capitalization?
Replimune Group, Inc.'s market capitalization is approximately $825.7M.
Get the full picture on Replimune Group, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.